Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akebia Therapeutics (NQ: AKBA )

0.5604 -0.0028 (-0.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Akebia Therapeutics

< Previous 1 2 3 4 5 Next >
US Stocks Turn Lower; S&P 500 Down 1%
U.S. stocks turned lower toward the end of trading, with the Dow Jones dropping around 300 points on Thursday. The Dow traded down 0.88% to 32,510.83 while the NASDAQ fell 1.34% to 11,421.06. The S&P... 
Via Benzinga
Why JD.com Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Akebia Therapeutics Earnings Preview
 
Via Benzinga
Looking Into Akebia Therapeutics's Return On Capital Employed
 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  Thursday saw 177 companies set new 52-week lows. 
Via Benzinga
Akebia Therapeutics Return On Capital Employed Insights
  
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Why Fulcrum Therapeutics Shares Are Trading Lower By Over 55%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Bridger Aerospace Group Holdings, Inc. (NASDAQ: BAER) shares jumped 129.6% to $10.15. Jeffrey E. Kelter reported a 22.4% stake in a 13D filing on Thursday. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study
 
Via Benzinga
Akebia Therapeutics: Q2 Earnings Insights
Akebia Therapeutics (NASDAQ:AKBA) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Why Beyond Meat Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
Gainers Cingulate Inc (NASDAQ: CING) rose 85.7% to $2.08 in pre-market trading after the company disclosed top-line results from Fed/Fast study of lead asset CTx-1301 for ADHD. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Why TripAdvisor Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 69.1% to $0.7948 in pre-market trading after the company requested withdrawal of registration statement. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off another day of trading with a breakdown of the biggest pre-market stock movers for trader need to kno about Wednesday! 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Planned Government Move To Expand Access To Drugs For End-Stage Renal Disease Patients Could Shine The Spotlight On Unicycive
In the U.S., reimbursement of dialysis expenses by the Centers for Medicare & Medicaid Services (CMS) is done using a prospective payment system (PPS) which enables the payout of a predetermined amount... 
Via Benzinga
Akebia Therapeutics Earnings Preview
Akebia Therapeutics (NASDAQ:AKBA) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Akebia... 
Via Benzinga
Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells
You may remember learning that mitochondria are the powerhouse of the cells, but do you know the dangers that result if these cell superheroes get sick? 
Via TheNewswire.com
Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells
You may remember learning that mitochondria are the powerhouse of the cells, but do you know the dangers that result if these cell superheroes get sick?  
Via Benzinga
Why Missfresh Shares Are Trading Lower; Here Are 30 Stocks Moving Premarket
Gainers M-tron Industries, Inc. (NASDAQ: MPTI) rose 57.9% to $24.00 in pre-market trading after surging 10% on Friday. M-tron Industries completed its earlier announced separation from The LGL Group,... 
Via Benzinga
Why Kiora Pharmaceuticals Is Trading Lower By Around 22%; Here Are 26 Stocks Moving Premarket
Gainers 9 Meters Biopharma, Inc. (NASDAQ: NMTR) rose 31.4% to $0.2720 in pre-market trading after the company disclosed final results from Phase 2 VIBRANT study, End-of-Phase 2 meeting with the FDA for... 
Via Benzinga
How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication
By David Willey, Benzinga 
Via News Direct
How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication
Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States. 37 million American adults have CKD and more than 600,000... 
Via TheNewswire.com
Exposures Product Safety
How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication
Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States. 37 million American adults have CKD and more than 600,000... 
Via Benzinga
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.